The PsychENCODE Consortium was founded by the U.S. National Institutes of Health in 2015 to study the role of rare genetic variants involved in several psychiatric disorders. PsychENCODE aims to create a public resource of genomic data gathered from 1,000 healthy and disease-affected post-mortem brains reflecting different developmental periods.
PsychENCODE will first focus on autism spectrum disorder, bipolar disorder, and schizophrenia, and then move on to other disorders.[1]
Participating organizations
editAs of December 2018, participating organizations include:
- Duke University
- Icahn School of Medicine at Mount Sinai
- Johns Hopkins University
- Lieber Institute for Brain Development
- Mayo Clinic
- National Institute of Mental Health
- Sage Bionetworks
- SUNY Downstate Medical University
- SUNY Upstate Medical University
- University of California Los Angeles
- University of Chicago
- University of Illinois
- University of Massachusetts Medical School
- University of North Carolina
- University of Southern California
- Yale University[2]
References
edit- ^ Akbarian, S; Liu, C; Knowles, JA (2015). "The PsychENCODE project". Nat Neurosci. 18: 1707–12. doi:10.1038/nn.4156. PMC 4675669. PMID 26605881.
- ^ "PsychENCODE". psychENCODE.org. Retrieved 2018-12-26.
.svg){kind=icon} | This psychiatry-related article is a stub. You can help Wikipedia by expanding it. |